Reconstructive Breast Surgery/Management of Breast Implants (7.01.22)
Blue Shield of California medical policy 7.01.22 on reconstructive breast surgery and management of breast implants has an effective date of October 1, 2026. The annual review updated the policy statement, guidelines and literature review. Reconstructive breast surgery may be considered medically necessary after a medically necessary mastectomy, accidental injury or trauma. Explantation of a silicone gel-filled implant may be considered medically necessary for documented rupture, infection, extrusion, Baker class IV contracture, or as an adjunct to surgical treatment of breast cancer. A saline-filled implant follows similar indications, and a documented rupture qualifies only when the implant was originally placed for reconstructive purposes. Preventive explantation to reduce remote risk of anaplastic large cell lymphoma, B cell lymphoma or squamous cell carcinoma is listed as investigational.